MarketPeel
Insider Trading Intelligence
JH

Jill Ann Howe

LCTX
CHIEF FINANCIAL OFFICER · LINEAGE CELL THERAPEUTICS, INC. · CIK 0001892397
FILING MIX · LIFETIME100%/0%
BUYS
7
SELLS
0
TOTAL VALUE
$18.2K
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
1,050,000
AVG SELL PX
TRADE KIND
SHOWING 7 / 7
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Jill Ann Howe, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+0.29%+0.98%-0.69%-0.69%
14d2+100.00%+1.56%+1.02%+0.54%+0.54%
30d2+50.00%-4.28%+0.99%-5.27%-5.27%
60d2+50.00%+0.94%+3.24%-2.30%-2.30%
90d2+100.00%+6.25%+3.56%+2.68%+2.68%
180d2+50.00%-4.90%+3.29%-8.19%-8.19%
1y2+100.00%+111.06%+15.53%+95.53%+95.53%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LCTX · 1,050,000 shares · as of Mar 5, 2026
0262,500525,000787,5001,050,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 7 buys / 0 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,050,0001,050,000Mar 5, 2026Mar 6, 2026View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
750,000750,000Mar 10, 2025Mar 12, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
15,000$0.59$8.8K25,500Nov 26, 2024Nov 26, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
10,500$0.89$9.3K10,500Aug 16, 2024Aug 19, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
650,000650,000Mar 7, 2024Mar 8, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Mar 9, 2023Mar 10, 2023View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,000,0001,000,000Nov 14, 2022Nov 16, 2022View →
Other insiders · LCTX
Loading peer insiders…
About this filer
CIK 0001892397
ROLE
Chief Financial Officer
PRIMARY
LCTX
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001892397DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback